{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T22:17:10Z","timestamp":1790979430267,"version":"4.1.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:sec id=\"ab-doi220040-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Other than single-center case studies, little is known about generalized pustular psoriasis (GPP) flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220040-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess GPP flares and their treatment, as well as differences between patients with and patients without flares documented in US electronic health records (EHRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220040-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included adult patients with GPP (\n                      <jats:italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n                      code L40.1) identified in Optum deidentified EHR data between July 1, 2015, and June 30, 2020. The index GPP diagnosis was the first occurrence in the EHR, with no coded history of GPP for at least 6 months prior. Flare episodes were identified using an algorithm based on diagnosis coding, care setting, type of clinician, GPP disease terms, and flare terms and attributes in the EHR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220040-7\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Flare episodes were characterized by the frequency of occurrence per patient, the care setting in which they were identified, the type of specialist managing the episode, associated symptoms, and the type of treatment before, during, and after the episode. Patients were divided into groups based on whether or not they had a flare episode documented in their EHR. Comparisons were made between the groups based on demographic characteristics, comorbidity burden, health care use, and treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220040-8\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 1535 patients with GPP (1018 women [66.3%]; mean [SD] age, 53.4 [14.7] years), 271 had 513 flares documented. Compared with patients without flares, patients with flares had a 34% higher mean (SD) Charlson Comorbidity Index score (2.80 [3.11] vs 2.09 [2.52]), were almost 3 times more likely to have inpatient visits (119 of 271 [44%] vs 194 of 1264 [15%]), were more than twice as likely to have emergency department (ED) visits (126 of 271 [47%] vs 299 of 1264 [24%]), and had higher use of almost all treatment classes. Flares were identified in outpatient (271 of 513 [53%]), inpatient (186 of 513 [36%]), and ED (48 of 513 [9%]) settings. The most common treatments during flares were topical corticosteroids (35% of episodes [178 of 513]), opioids (21% [106 of 513]), other oral treatments, (eg, methotrexate, cyclosporine, tacrolimus; 13% [67 of 513]), and oral corticosteroids (11% [54 of 513]). Almost one-fourth of flare episodes (24% [122 of 513]) had no dermatologic treatment 30 days before, during, or 30 days after a flare episode.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-doi220040-9\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This cohort study suggests that there is significant unmet need for the treatment of GPP and its flares, as evidenced by patients seeking treatment in inpatient and ED settings, as well as the lack of advanced treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.3142","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T11:07:21Z","timestamp":1660129641000},"page":"1142","source":"Crossref","is-referenced-by-count":37,"title":["Understanding Flares in Patients With Generalized Pustular Psoriasis Documented in US Electronic Health Records"],"prefix":"10.1001","volume":"158","author":[{"given":"Carla L.","family":"Zema","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendell C.","family":"Valdecantos","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Weiss","sequence":"additional","affiliation":[{"name":"Optum, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Krebs","sequence":"additional","affiliation":[{"name":"Optum, Minneapolis, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan M.","family":"Menter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Baylor University Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi220040r1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3388","author":"Bachelez","year":"2020","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"doi220040r2","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s13555-021-00612-x","article-title":"Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options.","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"9","key":"doi220040r3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","article-title":"An update on generalized pustular psoriasis.","volume":"15","author":"Gooderham","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"doi220040r4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","article-title":"Clinical and genetic differences between pustular psoriasis subtypes.","volume":"143","author":"Twelves","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"doi220040r5","doi-asserted-by":"publisher","DOI":"10.2147\/PTT","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"doi220040r6","doi-asserted-by":"publisher","DOI":"10.2147\/PTT","author":"Benjegerdes","year":"2016","journal-title":"Psoriasis (Auckl)"},{"issue":"3","key":"doi220040r7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1080\/1744666X.2019.1708193","article-title":"The clinical, humanistic, and economic burden of generalized pustular psoriasis: a structured review.","volume":"16","author":"Kharawala","year":"2020","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"doi220040r8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1080\/03007995.2021.1894108","article-title":"Economic burden of generalized pustular psoriasis and palmoplantar pustulosis in the United States.","volume":"37","author":"Hanna","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"doi220040r9","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/jde.v48.11","article-title":"Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database.","volume":"48","author":"Okubo","year":"2021","journal-title":"J Dermatol"},{"issue":"10","key":"doi220040r10","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1111\/jde.v48.10","article-title":"Patient characteristics and burden of disease in Japanese patients with generalized pustular psoriasis: results from the Medical Data Vision claims database.","volume":"48","author":"Morita","year":"2021","journal-title":"J Dermatol"},{"issue":"45","key":"doi220040r11","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023068","article-title":"Association between mutation of interleukin 36 receptor antagonist and generalized pustular psoriasis: a PRISMA-compliant systematic review and meta-analysis.","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"doi220040r12","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1111\/jdv.2018.32.issue-10","article-title":"Generalized pustular psoriasis: a review and update on treatment.","volume":"32","author":"Hoegler","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"doi220040r13","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3892\/ijmm","article-title":"An update on genetic basis of generalized pustular psoriasis.","volume":"47","author":"Zhou","year":"2021","journal-title":"Int J Mol Med"},{"key":"doi220040r14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/jdv.13282","article-title":"Pustular psoriasis and psoriatic arthritis: 13 cases reported in a multidisciplinary unit.","volume":"30","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"doi220040r15","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1016\/j.jaad.2011.05.038","article-title":"Psoriasis and palmoplantar pustulosis associated with tumor necrosis factor-a inhibitors: the Mayo Clinic experience, 1998 to 2010.","volume":"67","author":"Shmidt","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"doi220040r16","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/ijd.2014.53.issue-6","article-title":"Clinical profile, morbidity, and outcome of adult-onset generalized pustular psoriasis: analysis of 102 cases seen in a tertiary hospital in Johor, Malaysia.","volume":"53","author":"Choon","year":"2014","journal-title":"Int J Dermatol"},{"key":"doi220040r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.008","author":"Miyachi","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi220040r18","doi-asserted-by":"publisher","first-page":"271","DOI":"10.2165\/11586900-000000000-00000","article-title":"Clinical and laboratory features in acute generalized pustular psoriasis: a retrospective study of 34 patients.","volume":"12","author":"Borges-Costa","year":"2011","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"doi220040r19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s13555-021-00493-0","article-title":"Unmet medical needs in the treatment and management of generalized pustular psoriasis flares: evidence from a survey of Corrona Registry dermatologists.","volume":"11","author":"Strober","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"doi220040r20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0923-1811(02)00142-1","article-title":"A survey of psoriasis patients in Japan from 1982 to 2001.","volume":"31","author":"Kawada","year":"2003","journal-title":"J Dermatol Sci"},{"issue":"1","key":"doi220040r21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2340\/00015555766871","article-title":"Generalized pustular psoriasis in Japan: two distinct groups formed by differences in symptoms and genetic background.","volume":"76","author":"Ohkawara","year":"1996","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"doi220040r22","first-page":"97","article-title":"Psoriasis: development and fatal complications.","volume":"118","author":"Roth","year":"1991","journal-title":"Ann Dermatol Venereol"},{"issue":"5","key":"doi220040r23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/bjd.1971.85.issue-5","article-title":"The prognosis of generalized pustular psoriasis.","volume":"85","author":"Ryan","year":"1971","journal-title":"Br J Dermatol"},{"key":"doi220040r24","author":"Kotowsky"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2794824\/jamadermatology_zema_2022_oi_220040_1666117428.9272.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T08:34:55Z","timestamp":1700901295000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2794824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,1]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.3142","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,1]]}}}